Related references
Note: Only part of the references are listed.OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.
Mansoor Raza Mirza et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Late Breaking Abstract An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Y. Drew et al.
GYNECOLOGIC ONCOLOGY (2018)
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Heidi J. Gray et al.
GYNECOLOGIC ONCOLOGY (2018)
Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.
Benjamin A. Teply et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
Fatima Karzai et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander et al.
LANCET ONCOLOGY (2018)
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Noel Clarke et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Harveer Dev et al.
NATURE CELL BIOLOGY (2018)
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
J. Ettl et al.
ANNALS OF ONCOLOGY (2018)
TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
Shaveta Vinayak et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA plus ).
Jennifer Keating Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander et al.
BRITISH JOURNAL OF CANCER (2018)
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
S. A. Hurvitz et al.
EUROPEAN JOURNAL OF CANCER (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
Graziela Z. Dal Molin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies
Silpa Nuthalapati et al.
CLINICAL PHARMACOKINETICS (2018)
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2017)
Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
Pierre Chabot et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
Florian Engert et al.
ONCOTARGET (2017)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Yung-Jue Bang et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation
Rajendar K. Mittapalli et al.
PHARMACEUTICAL RESEARCH (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
Helena Margaret Earl et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Mallika S. Dhawan et al.
CLINICAL CANCER RESEARCH (2017)
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
Shin Nishio et al.
CANCER SCIENCE (2017)
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors
Tadaaki Nishikawa et al.
CANCER SCIENCE (2017)
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Jacob D. Soumerai et al.
CLINICAL CANCER RESEARCH (2017)
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo et al.
CLINICAL CANCER RESEARCH (2017)
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit et al.
CLINICAL CANCER RESEARCH (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study
Brian G. Czito et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Richard H. Wilson et al.
BRITISH JOURNAL OF CANCER (2017)
A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
J. K. Litton et al.
ANNALS OF ONCOLOGY (2016)
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Donna L. Nile et al.
BMC CANCER (2016)
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
Shivaani Kummar et al.
INVESTIGATIONAL NEW DRUGS (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer
Lawrence Leichman et al.
ONCOLOGIST (2016)
Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites
M. Verheij et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
Hitomi Mori et al.
PLOS ONE (2016)
PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.
Isabelle Ray-Coquard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
J. Bendell et al.
ANNALS OF ONCOLOGY (2015)
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
M. R. Middleton et al.
ANNALS OF ONCOLOGY (2015)
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
Hidenori Mizugaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
Andrew Gabrielson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
Minesh P. Mehta et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
Sebastian Eustermann et al.
MOLECULAR CELL (2015)
PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain
Jennine M. Dawicki-McKenna et al.
MOLECULAR CELL (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
Ashleigh Herriott et al.
ONCOTARGET (2015)
Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer).
Sarina Anne Piha-Paul et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146.
Kathy Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G. Del Conte et al.
BRITISH JOURNAL OF CANCER (2014)
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
Eiji Kubota et al.
CELL CYCLE (2014)
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
Maha Hussain et al.
INVESTIGATIONAL NEW DRUGS (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu et al.
LANCET ONCOLOGY (2014)
PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage
Benu Brata Das et al.
NUCLEIC ACIDS RESEARCH (2014)
A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Ruth Plummer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran et al.
EUROPEAN UROLOGY (2013)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Maike Ihnen et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Christopher J. Lord et al.
NATURE MEDICINE (2013)
Touching base with PARPs: moonlighting in the repair of UV lesions and double-strand breaks
Alex Pines et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Germline BRCA1 mutations increase prostate cancer risk
D. Leongamornlert et al.
BRITISH JOURNAL OF CANCER (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Arun Rajan et al.
CLINICAL CANCER RESEARCH (2012)
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Jens Samol et al.
INVESTIGATIONAL NEW DRUGS (2012)
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Bryan A. Gibson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BRCAness: Finding the Achilles Heel in Ovarian Cancer
Georgios Rigakos et al.
ONCOLOGIST (2012)
A review of PARP inhibitors: from bench to bedside
C. Underhill et al.
ANNALS OF ONCOLOGY (2011)
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
O. A. Khan et al.
BRITISH JOURNAL OF CANCER (2011)
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
Z. Kote-Jarai et al.
BRITISH JOURNAL OF CANCER (2011)
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Yvette Drew et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
David J. Gallagher et al.
CLINICAL CANCER RESEARCH (2010)
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
R. A. Dent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.
G. Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
The potential role and application of PARP inhibitors in cancer treatment
Anthony J. Chalmers
BRITISH MEDICAL BULLETIN (2009)
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Helen E. Bryant et al.
EMBO JOURNAL (2009)
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
K. Gudmundsdottir et al.
ONCOGENE (2006)
Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks
N Saleh-Gohari et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Breast and ovarian cancer
R Wooster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition
A Tutt et al.
TRENDS IN MOLECULAR MEDICINE (2002)
Share Paper
